Rodney J. Landreneau, MD Professor of Surgery Heart, Lung & Esophageal Surgery Institute University of Pittsburgh Medical Center Management of Non-Small.

Slides:

Advertisements

Similar presentations

Advertisements

Pulmonary Stereotactic Ablative Radiotherapy:

Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.

DEBATE: What is the Optimal Sequence of Therapies for Stage II-III Adenocarcinoma of the Proximal Stomach? Michael A. Choti, MD Department of Surgery UT.

Early Stage NSCLC: The Role of Chemotherapy Eric Vallieres, MD.

Staging. Treatment by Stage For early stage lung cancers, surgery or radiation alone For larger tumors (>4 cm) and N+, chemotherapy should be added.

ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.

Matthew Kilmurry, M.D. St. Mary’s General Hospital Grand River Hospital.

Giving Induction Radiation in Addition to Chemotherapy Is Not Associated with Improved Survival of NSCLC Patients with Operable Mediastinal Nodal Disease.

BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.

A Propensity-matched Study of Lobectomy Versus Segmentectomy for Radiologically Pure Solid Small-sized Non-small Cell Lung Cancer Terumoto Koike 1, Seijiro.

Prof Ramesh S Bilimagga President AROI Group Medical Director - HCG.

AATS Postgraduate Course April 26, 2015 N2 - Current Evidence: Is There Role for Surgery? Is There a Role for Postop Radiation for Surprise N2? Linda W.

SURGEONS ROLE AND INVOLVEMENT IN SBRT PROGRAM Stephen R. Hazelrigg, M.D. Professor and Chair, Cardiothoracic Surgery Southern Illinois University, School.

Sublobar Resection and Intraoperative Brachytherapy for Lung Cancer: ACOSOG Update Rodney J. Landreneau, MD Professor of Surgery The Heart Lung and Esophageal.

SURGERY FOR NSCLC GREG CHRISTODOULIDES MD, FACS, FCCP, FESTS

Optimal use of adjuvant chemotherapy for patients with stage I, II, or IIIA disease Francesco Grossi Oncologia Medica A Disease Management Team - Lung.

1 Non–Small-Cell Lung Cancer Diagnosis and Staging EvaluationPurpose Physical examinationIdentify signs Chest x-rayDetermine position, size, number of.

Finding N.E.M.O. Marvin R. Balaan, MD, FCCP System Division Director, Division of Pulmonary and Critical Care Medicine Allegheny Health Network, Pittsburgh.

Pneumonectomy for Locally Advanced Lung Cancer after Neoadjuvant Concurrent Chemo-radiation Therapy K. Okabe, H. Tao, T. Tanaka, T. Hayashi, K. Yoshiyama,

Intergroup trial CALGB 80101

Howard M. Sandler, MD University of Michigan Medical School

Management of Locally Advanced NSCLC Shilpen Patel MD FACRO Department of Radiation Oncology, University of Washington, Seattle, WA.

The effect of surgeon volume on procedure selection in non-small cell lung cancer surgeries Dr. Christian Finley MD MPH FRCSC McMaster University.

#1008 New Strategies in Treatment of Lung Cancer November 9 to 12 Patrick Ross, Jr. MD, PhD Assistant Professor of Surgery Division of Surgical Thoracic.

Long-term follow-up of a prospective trial of pre-operative external-beam radiation and post-operative brachytherapy for retroperitoneal sarcoma LA Mikula,

Pancreatic Cancer Ali Shamseddine MD Proessor of Medicine AUBMC

Adjuvant Therapy of Colon Cancer 2005 Daniel G. Haller, M.D. Abramson Cancer Center at the University of Pennsylvania Philadelphia PA.

What to do in stage III non small-cell lung cancer? Miklos Pless 28. November 2013.

Postoperative Radiotherapy for Patients with Stage II or III Nonsmall Cell Lung Cancer treated with Sublobar Resections: A SEER Registry Analysis Scott.

Delivering clinical research to make patients, and the NHS, better OG neoadjuvant therapy Brachytherapy Stephen Falk dd/mm/yyyy.

Dr Purvish M Parikh MD, DNB, FICP, PhD, ECMO, CPI, MBA 12 th July 2014, Kolkata 17th ICRO PG Teaching Course.

Surgery for lung cancer – a review

EARLY PROGRESSION IN PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS AN ANALYSIS FROM A PHASE III RANDOMIZED PROSPECTIVE TRIAL (EORTC 62961/ESHO) OF NEOADJUVANT.

THE OUTBACK TRIAL A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared.

on behalf of the ACOSOG Z4032 Investigators

Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl,

Phase III Study of Concurrent Chemotherapy and Radiotherapy (CT/RT) versus CT/RT followed by Surgical Resection for Stage IIIA(pN2) NSCLC Outcomes Update.

Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,

Adjuvant chemotherapy in Rectal Cancer?. What is the evidence for adjuvant chemotherapy? Do patients achieving a pathological complete response need chemotherapy?

Adjuvant Radiation is Not Associated with Improved Survival in Patients with Positive Margins Following Lobectomy for Stage I & II Non-Small Cell Lung.

Time to Secondary Resistance (TSR) After Interruption of Imatinib: Updated Results of the Prospective French Sarcoma Group Randomized Phase III Trial on.

Approaching early stage disease

Poster # 18, abstract # 4530 Long term results of a phase III study investigating chemoradiation with and without surgery in locally advanced squamous.

Patterns of Care in Medical Oncology Treatment of Metastatic Colon Cancer.

The Role of Preoperative Approaches in Localized Gastro Esophageal Cancers David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan-Kettering.

Joan Schiller, MD Professor of Medicine Chief, Division of Hematology/Oncology University of Texas Southwestern Medical Center Deputy Director Simmons.

Cancer Education Day May 13, Surgery for Lung Cancer Dr A Elalem Thoracic surgeon Windsor Regional hospital.

What Factors Predict Outcome At Relapse After Previous Esophagectomy And Adjuvant Therapy in High-Risk Esophageal Cancer? Edward Yu 1, Patricia Tai 5,

Wedge Resection for Small Peripheral Lung Cancer is Appropriate Douglas E. Wood, MD, FACS, FRCSEd (ad hom) Professor and Chief Division of Cardiothoracic.

Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.

Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer in the Elderly: A Population-Based Study in Ontario, Canada JOURNAL OF CLINICAL ONCOLOGY, VOLUME 30.

Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,

Emily Tanzler, MD Waseet Vance, MD

Treatment of Stage I and II Non-small Cell Lung Cancer

Prognosis of younger patients in non-small cell lung cancer

Adjuvant chemotherapy in NSCLC

Outcomes of Sublobar Resection Versus Lobectomy for Stage I Non–Small Cell Lung Cancer: A 13-Year Analysis Amgad El-Sherif, MD, William E. Gooding, MS,

Treatment of Stage I and II Non-small Cell Lung Cancer

What is the optimal pre-op therapy for esophagus and GE junction cancers?

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection Morihito Okada,

Adjuvant Radiation is Required for Gastric Cancer

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system Shamus R.

Oncologic Outcomes After Surgical Resection of Subcentimeter Non-Small Cell Lung Cancer Matthew J. Schuchert, MD, Arman Kilic, BS, Arjun Pennathur, MD,

Treatment of Stage I and II Non-small Cell Lung Cancer

Lobar and sublobar resection with and without brachytherapy for small stage IA non– small cell lung cancer Hiran C. Fernando, FRCS, FRCSEd, Ricardo S.

Analysis of longitudinal quality-of-life data in high-risk operable patients with lung cancer: Results from the ACOSOG Z4032 (Alliance) multicenter randomized.

Arman Kilic, BS, Matthew J. Schuchert, MD, Brian L

Matthew J. Schuchert, MD, Brian L

Presentation transcript:

Rodney J. Landreneau, MD Professor of Surgery Heart, Lung & Esophageal Surgery Institute University of Pittsburgh Medical Center Management of Non-Small Cell Lung Cancer St. Margaret Grand Rounds September 10,2009

Management of Non-Small Cell Lung Cancer CT surveillance for lung cancer Sublobar Resection vs. Lobectomy Role of surgical resection for regionally advanced lung cancer Adjuvant Systemic Therapy for regionally advanced “resectable” lung cancer CT surveillance for lung cancer Sublobar Resection vs. Lobectomy Role of surgical resection for regionally advanced lung cancer Adjuvant Systemic Therapy for regionally advanced “resectable” lung cancer

Lung Cancer Surveillance

Original Article Survival of Patients with Stage I Lung Cancer Detected on CT Screening The International Early Lung Cancer Action Program Investigators N Engl J Med Volume 355(17): October 26, 2006

Kaplan-Meier Survival Curves for 484 Participants with Lung Cancer and 302 Participants with Clinical Stage I Cancer Resected within 1 Month after Diagnosis The International Early Lung Cancer Action Program Investigators. N Engl J Med 2006;355:

Conclusion ● Annual spiral CT screening can detect lung cancer that is curable ● Comparable screening efficacy as mammographic screening for breast cancer (prevalence 1.6%; incidence 0.6%) ● Cost effective - low energy, fast scanning about $200 ● Treatment of early stage disease less expensive than advanced disease

Controversy

CT scans have radiation risks and sometimes detect cancers that would not have progressed, leading to risky procedures like biopsies and lung surgery when not needed. lung surgery lung surgery

The National Cancer Institute started in 2002 the $200 million “National Lung Screening Trial” comparing death rates among 55,000 people randomly assigned to have CT scans or chest X- rays. Results are not expected until 2010.

“Sublobar Resection” or “Lobectomy” for stage I lung cancer

Standard of Care For Peripheral Nodules 1940’s Pneumonectomy 1960’s Lobectomy 1990’s ?Segmentectomy/Wedge (and adjuvant local/systemic Rx) Surgical Resection of the Lung

Errett LE et al J Thorac Cardiovasc Surg Nov;90(5): Sublobar Resection vs. Lobectomy for Stage 1 Non-Small Cell Lung Cancer

Randomized Trial of Lobectomy Versus Limited Resection for T1 N0 Non-Small Cell Lung Cancer (125 Lobectomy, 122 Limited Resection) RJ Ginsberg, LV Rubinstein and Lung Cancer Study Group Ann Thorac Surg 1995;60:615-23

Lobectomy vs Limited Resection Time to death (from any cause) by treatment logrank p=0.088 (one-tailed) Ginsberg and Rubinstein Ann Thorac Surg

Wedge Resection Versus Lobectomy for Stage I (T1 N0 M0) Non-Small Lung Cancer Landreneau, et.al., J Thorac Cardiovasc Surg 1997;113:

Wedge vs Lobectomy for Stage I NSCLC p=0.889 Landreneau, et.al., J Thorac Cardiovasc Surg 1997;113:

Wedge vs Lobectomy for Stage I NSCLC Open WR VATS WR Vs.LobeP< Op Mortality (%)00Vs * Postop Stay (days) Vs * Local Recur (%) 1715 Vs * Local/Systemic Recurrence (%) 2423vs * *- all WR (n=95) vs. Lobe (n=124) Statistical Methods: Life Table Analyses Obtained by Log Rank and Wilcoxson Tests Landreneau, et.al., J Thorac Cardiovasc Surg 1997;113:

! Local Recurrence !

Adjuvant Radiation Therapy ● External beam radiation therapy - Potential risk of increased injury to surrounding pulmonary parenchyma ● What is efficacy of intraoperative brachytherapy when external beam radiation may otherwise be applied?

Intraoperative Brachytherapy ● Not a new concept for lung cancer ● Mostly used for Stage IIIA disease - close or positive margins ● Improved local control ● What is it’s role in high risk patients with totally resectable disease where lobar resection is not feasible and adjuvant radiotherapy is recommended?

Comparison Between Sublobar Resection and 125Iodine Brachytherapy After Sublobar Resection in High-Risk Patients with Stage I Non–Small-Cell Lung Cancer Comparison Between Sublobar Resection and 125Iodine Brachytherapy After Sublobar Resection in High-Risk Patients with Stage I Non–Small-Cell Lung Cancer R. Santos, A. Colonias, D. Parda, M. Trombetta, RH Maley, R. Macherey, S. Bartley, T. Santucci, RJ Keenan, RJ Landreneau Surgery 2003, Oct;134(4): 691-7

Sublobar Resection (n=102) Sublobar Resection With Brachy (n=96) Local Recurrence19 (18.6%)1 (1%) p=.0001 Hospital Mortality0 (0%)3 (3%) p=ns Hospital Stay7 days8 days p=ns Survival % 1, 2, 3 and 4 year93, 73, 68, 60%96, 82, 70, 67% p=ns Systemic Recurrence 29 (28.4)22 (23%) p=ns Pre-op FEV 1% predicted 65%53% p=nsResults The FEV 1 did not change postoperatively in the sublobar resection with brachytherapy group in the interval of follow-up

Lobectomy vs Sublobar Resection “Effect of Tumor Size on Prognosis in Patients with Non-Small Cell Lung Cancer: The Role of Segmentectomy as a Type of Lesser Resection” “Effect of Tumor Size on Prognosis in Patients with Non-Small Cell Lung Cancer: The Role of Segmentectomy as a Type of Lesser Resection” Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, Nakagawa A, Tsubota N. “J Thorac Cardiovasc Surg Jan;129(1):87-93” An evaluation of surgical resection in 1272 NSCLC patients

TUMOR SIZE Segmental ResectionLobectomy Wedge Resection 20 mm or less mm More than 30 mm Lobectomy vs Sublobar Resection 5 Year Cancer Specific Survival “Stage I” “Okada, M, et al J Thorac Cardiovasc Surg Jan;129(1):87-93”

Efficacy of Anatomic Segmentectomy in the Treatment of Stage I NSCLC Matthew J. Schuchert M.D., Brain L. Pettiford M.D., Samuel Keeley M.D., Thomas A. D’Amato M.D., Ph.D., Arman Kilic B.S., Hiran C. Fernando M.D., John Close M.A., Ricardo Santos M.D., James R. Landreneau, James D. Luketich M.D., Rodney J. Landreneau M.D. Division of Thoracic Surgery Heart, Lung and Esophageal Surgery Institute UPMC Health System Pittsburgh, Pennsylvania

Patient and Tumor Characteristics Stage IA Anatomic Segmentectomy (n=182) Lobectomy (n=246) Stage IA109 (60%) 114 (46%) Tumor Size Mean (cm) Range (cm) Schuchert MJ., et. Al.; STS 2007

Stage IA – Segmentectomy vs Lobectomy Cumulative Survival Time (months) Lobectomy Segmentectomy log rank = Schuchert MJ., et. Al.; STS 2007 Overall Survival

Recurrence Patterns - Stage IA Anatomic Segmentectomy (n=109) Lobectomy (n=114) P Value NED 97 (89%) 102 (83.3%) NS Recurrence Locoregional Distant 12 (11.0%) 5 (4.6%) 7 (6.4%) 12 (10.5 %) 6 (5.3%) NS Follow-Up (Mos) <0.05 Schuchert MJ., et. Al.; STS 2007

Anatomic Segmentectomy Favorable Criteria for Anatomic Segmentectomy Peripheral location (outer 1/3) Small Tumors: < 2 cm in diameter Pathologic Margin > 1 cm (Margin/Tumor ratio>1) Age >75 Marginal pulmonary function Ground glass opacities – Bronchoalveolar UPMC Experience 452 Anatomic Segmentectomies Stage I NSCLC Stage II-III NSCLC - 31 Metastasectomies - 9 Benign Neoplasms - 53 Inflammatory/Granulomatous - 15 Bullous Disease - 5 Infection/Abscess - 1 Trauma ACOSOG Z0030: Mortality 3%; Complications 46% UPMC: Mortality 1.1%; Complications 32%

Sublobar Resection?

Sublobar Resection vs. Lobectomy?

Induction (pre-operative ) Chemo-radiotherapy for Stage III-a non-small cell lung cancer Standard of Care ???

Intergroup trial 0139 Chemo-radiation vs Chemo- radiation followed by surgical resection of Stage IIIa NSCLC Kathy Albain et al. ASCO 2005 Lancet 2009;374:379-86

Adjuvant Chemotherapy in NSCLC: A new standard of care?

N Engl J Med 2004;350:351-60

New Engl J Med 2004;350: %

NEJM 2004;350: Chemotherapy better

ASCO 2004 CALGB 9633 Chemotherapy Observation 71% 59% HR 0.62 p=0.028 NCIC BR 10 Chemotherapy Observation 69% 54% HR 0.7 p=0.012 YRS 5yrs 4yrs

ASCO 2005 ANITA : OS months Survival Distribution Function [ ] Hazard Ratio 0.013P-value Median months NVB + CDDP OBS. Obs NVB + CDDP

ChemotherapyObservation MOS 95 months 78 months P value 0.10 HR (90% CI) 0.80 ( ) Survival Time (Years) Probability Observation Chemo ASCO 2006 (137/155 of total events) ABSTR #7007 CALGB OVERALL SURVIVAL

Adjuvant Chemotherapy Standard of Care - Stages IIA-B - IIIA NSCLC - Maybe Larger IB ??? ● Good performance status patients with “R0” Anatomic Resection - Stages IIA-B - IIIA NSCLC - Maybe Larger IB ???

City of Pittsburgh Pennsylvania Thank You

Still Empiric Therapy Approach!!

Drug Resistance Testing

Clinical Correlation in Non-Small Cell Lung Cancer

9 LDR IDR EDR

10

Completely Resected Stage IB-IIIA NSCLC + EDR-Assay Randomize Assay Directed Standard Therapy Correlative Studies Molecular Markers Proteomics Genomics Correlative Studies Molecular Markers Proteomics Genomics Registration vs. Survival Disease Free Survival Survival Disease Free Survival Schema for Future Clinical Trials

Future Directions Patients with micrometastisis Responders to Chemotx STD AD Improvement ?

Randomized Trial of Induction Chemotherapy Followed by Anatomic Lung Resection – Stage IIIA – SWOG 9900 Eric Vallieries 2007

S9900 S9900 Study Design ELIGIBLEELIGIBLE RANDOMIZEDRANDOMIZED PACLITAXEL CARBOPLATIN x3 cycles SURGERY ● Clinical Stage T2N0, T1-2N1, T3N0-1 ● Mediastinoscopy if LN > 1 cm on CT ● Stratification: IB/ IIA vs. IIB/ IIIA Pisters, et. Al. – ASCO 2005

Surgical Results Preop PCb N=168 Surgery Only N=167 Explored 149 (89%)* 162 (97%)** R0 Intent to Treat 84%84% Explored Explored94%89% Pneumonectomy16%16% Lobectomy68%68% Wedge/Segment5%11% Open/Close3%4% Incomplete Data 8%1% Path CR 10%- *19: Refusal, POD, death, medical, wrong arm, n/a **5: Medical, refusal, MD decision, n/a S9900 Pisters, et. Al. – ASCO 2005

Progression-Free Survival by Treatment Arm 05/09/2005, median F/U 31 mo Pisters, et. Al. – ASCO 2005

Overall Survival by Treatment Arm 05/09/2005, median F/U 31 mo Pisters, et. Al. – ASCO 2005

CS (n=154)S Only (n=160) N=7* (.045)N=4 (.025) Lobectomy Pneumonectomy 3 (.02) 4/24 (.17) Lobectomy Pneumonectomy 4 (.035) 0/26 [2R, 2L] *p=0.32 From: Eric Vallieries 2007 Randomized Trial of Induction Chemotherapy Followed by Anatomic Lung Resection – Stage IIIA – SWOG 9900

Depierre Randomized Preop Trial Preop Trial ● N=355 eligible, stages IB, II and IIIA (35% N2) ● MIP x2 Surgery (+2 adj: PR/path CR) Surgery alone ● Median survival 37 vs 26 months, p=0.15 Depierre JCO 2002

● Disease free survival 27 vs 13 mo, p=0.033 ● Risk of DM=0.54 [ ], p=0.01 ● Stage I-II: Risk death= 0.68 [ ], p=0.027 Depierre Randomized Preop Trial Preop Trial Continued Depierre JCO 2002

Results Overall Survival BLOTS9900Depierre PreopControlPreopControl Median OS (months) year (%) year (%) Pisters, et. Al. - ASCO 2005; JCO 2002

Management of Non-Small Management of Non-Small Cell Lung Cancer Lung Cancer Survival

Still Empiric Therapy Approach!!

Dr. Henschke has asserted that allowing hundreds of thousands of people to die in the meantime is unethical. Therefore, “off study” CT screening should be approved by insurance for high risk patients!